131 i-omburtamab

mAbexperimentalADC

Clinical trial activity

9 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Oct 1, 2001 (NCT00582608)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No
Payload
131-iodine

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 131i-8h9
  • 8h9
  • 8h9
  • 8h9 (131i)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05063357Phase 1Dec 31, 2021Invicro, LabCorp, Y-Mabs, Inc
NCT04743661Phase 2Oct 1, 2021Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium, Y-Mabs, Inc
NCT04022213Phase 2Jul 15, 2019Memorial Sloan-Kettering Cancer Center, Y-Mabs, Inc
NCT03275402Phase 2/Phase 3 (Phase 3)Sep 30, 2018Y-Mabs, Inc
NCT01502917Phase 1Dec 31, 2011Memorial Sloan-Kettering Cancer Center, Y-Mabs, Inc
NCT01099644Phase 1Apr 1, 2010Cornell University
NCT00089245Phase 1Jul 1, 2004Cornell University, National Cancer Institute (NCI), New York University
NCT00582608N/AOct 1, 2001Cornell University
NCT05064306N/AMemorial Sloan-Kettering Cancer Center, Y-Mabs, Inc
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Y-Mabs, IncFor profit6342011
Memorial Sloan-Kettering Cancer CenterAcademic/Hospital4232011
Cornell UniversityAcademic/Hospital3322001
National Cancer Institute (NCI)Government2022004
InvicroFor profit1012021
LabCorpFor profit1012021
New York UniversityAcademic/Hospital1012004
Pediatric Brain Tumor ConsortiumAcademic/Hospital1112021
8 organizations
Page 1 / 1